Phase III clinical trial of favipiravir in early-onset COVID-19 patients with severe risk factors
Phase 3
- Conditions
- COVID-19 patients with risk factors of progression to severe disease onset within 72 hours prior to
- Registration Number
- JPRN-jRCT2041210004
- Lead Sponsor
- Sakurai Tsutomu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 316
Inclusion Criteria
1.Patients with positive SARS-CoV-2 test result by RT-PCR or loop-mediated isothermal amplification (LAMP) method or antigen test.
2.Patient within 72 hours from onset of first COVID-19 symptom
3.Patients with risk factors of progression to severe disease
4.Have a negative pregnancy test before study treatment
5.Patients can obtain written informed consent from the patients.
6.Other
Exclusion Criteria
1.Patients receiving oxygen therapy prior to the start of study treatment.
2.Patients with any of COVID-19 clinical symptoms/findings of dyspnea or a respiratory rate of 30 breaths/min or more.
3.Patients with SARS-CoV-2 vaccinated
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method